Company

Avalo Therapeutics

As of the edition of 20 October 2026, Avalo Therapeutics runs 4 drugs; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Active1
Went quiet1
Stopped2
Total4

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
TNFSF14 Tumor necrosis factor ligand superfamily member 14Route A
GRIN1 Glutamate receptor ionotropic, NMDA 1Route A
GRIN2B Glutamate receptor ionotropic, NMDA 2BRoute A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Blood and lymph: 2 trials led
  • Mental health: 2 trials led
  • Cancer: 1 trials led